argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
Rhea-AI Summary
argenx (NASDAQ:ARGX) will report full year 2025 financial results and deliver a fourth quarter business update on Thursday, February 26, 2026 at 2:30 PM CET (8:30 AM ET).
The company said a live audio webcast and conference call will be available via the Investors section at argenx.com/investors, with a replay available for about one year. Dial-in access code: 3810049.
Positive
- None.
Negative
- None.
News Market Reaction – ARGX
In the Feb 19 session, ARGX gained 0.23%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 13 | Regulatory update | Positive | +1.8% | FDA acceptance of VYVGART sBLA with Priority Review and set PDUFA date. |
| Jan 12 | Strategic outlook | Positive | +0.9% | Preliminary 2025 net sales update and articulated 2026 strategic priorities. |
| Jan 06 | Conference appearance | Neutral | +0.4% | Announcement of presentation at J.P. Morgan Healthcare Conference with webcast. |
| Jan 05 | Leadership change | Neutral | -4.7% | CEO transition to Karen Massey and move of prior CEO to chair role. |
| Dec 15 | Clinical trial update | Negative | -3.1% | Discontinuation of UplighTED Phase 3 TED studies for futility after interim review. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Price generally moved in the direction implied by news tone, with leadership transition as the main divergence.
Over the past months, argenx reported strong VYVGART-driven sales growth, strategic 2026 priorities, and FDA priority review for an sBLA with a PDUFA date of May 10, 2026. Shares reacted positively to these updates, while the discontinuation of the UplighTED TED studies and a planned leadership transition drew negative responses. Against this backdrop, the newly announced February 26, 2026 earnings call sets expectations for full-year 2025 results and a Q4 business update.
AI-generated analysis. How Rhea-AI works. Not financial advice.
February 19, 2026
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 26, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2025 financial results and provide a fourth quarter business update.
A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.
Dial-in numbers:
Belgium 32 800 50 201
France 33 800 943355
Netherlands 31 20 795 1090
United Kingdom 44 800 358 0970
United States 1 888 415 4250
Japan 81 3 4578 9081
Switzerland 41 43 210 11 32
Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
